» Articles » PMID: 36178190

Identification of Orphan Ligand-receptor Relationships Using a Cell-based CRISPRa Enrichment Screening Platform

Overview
Journal Elife
Specialty Biology
Date 2022 Sep 30
PMID 36178190
Authors
Affiliations
Soon will be listed here.
Abstract

Secreted proteins, which include cytokines, hormones, and growth factors, are extracellular ligands that control key signaling pathways mediating cell-cell communication within and between tissues and organs. Many drugs target secreted ligands and their cell surface receptors. Still, there are hundreds of secreted human proteins that either have no identified receptors ('orphans') or are likely to act through cell surface receptors that have not yet been characterized. Discovery of secreted ligand-receptor interactions by high-throughput screening has been problematic, because the most commonly used high-throughput methods for protein-protein interaction (PPI) screening are not optimized for extracellular interactions. Cell-based screening is a promising technology for the deorphanization of ligand-receptor interactions, because multimerized ligands can enrich for cells expressing low affinity cell surface receptors, and such methods do not require purification of receptor extracellular domains. Here, we present a proteo-genomic cell-based CRISPR activation (CRISPRa) enrichment screening platform employing customized pooled cell surface receptor sgRNA libraries in combination with a magnetic bead selection-based enrichment workflow for rapid, parallel ligand-receptor deorphanization. We curated 80 potentially high-value orphan secreted proteins and ultimately screened 20 secreted ligands against two cell sgRNA libraries with targeted expression of all single-pass (TM1) or multi-pass transmembrane (TM2+) receptors by CRISPRa. We identified previously unknown interactions in 12 of these screens, and validated several of them using surface plasmon resonance and/or cell binding assays. The newly deorphanized ligands include three receptor protein tyrosine phosphatase (RPTP) ligands and a chemokine-like protein that binds to killer immunoglobulin-like receptors (KIRs). These new interactions provide a resource for future investigations of interactions between the human-secreted and membrane proteomes.

Citing Articles

Cell surface protein-protein interaction profiling for biological network analysis and novel target discovery.

Chen J, Fang M, Li Y, Ding H, Zhang X, Jiang X Life Med. 2025; 3(4):lnae031.

PMID: 39872863 PMC: 11749001. DOI: 10.1093/lifemedi/lnae031.


Novel secreted regulators of glucose and lipid metabolism in the development of metabolic diseases.

Wat L, Svensson K Diabetologia. 2024; 67(12):2626-2636.

PMID: 39180580 DOI: 10.1007/s00125-024-06253-x.


Orphan G protein-coupled receptors: the ongoing search for a home.

Jobe A, Vijayan R Front Pharmacol. 2024; 15:1349097.

PMID: 38495099 PMC: 10941346. DOI: 10.3389/fphar.2024.1349097.


Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform.

Yang L, Sheets T, Feng Y, Yu G, Bajgain P, Hsu K Sci Adv. 2024; 10(7):eadj2445.

PMID: 38354234 PMC: 10866537. DOI: 10.1126/sciadv.adj2445.


Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox.

Siepe D, Picton L, Garcia K ACS Synth Biol. 2023; 12(4):1081-1093.

PMID: 37011906 PMC: 10127277. DOI: 10.1021/acssynbio.2c00587.


References
1.
Wei Y, Ren X, Galbo Jr P, Moerdler S, Wang H, Sica R . KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021; 6(61). PMC: 9744578. DOI: 10.1126/sciimmunol.abf9792. View

2.
Papadimitriou E, Pantazaka E, Castana P, Tsalios T, Polyzos A, Beis D . Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer. Biochim Biophys Acta. 2016; 1866(2):252-265. DOI: 10.1016/j.bbcan.2016.09.007. View

3.
Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E . Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Front Immunol. 2019; 10:1179. PMC: 6558367. DOI: 10.3389/fimmu.2019.01179. View

4.
Clevers H, Nusse R . Wnt/β-catenin signaling and disease. Cell. 2012; 149(6):1192-205. DOI: 10.1016/j.cell.2012.05.012. View

5.
Martinez-Martin N . Technologies for Proteome-Wide Discovery of Extracellular Host-Pathogen Interactions. J Immunol Res. 2017; 2017:2197615. PMC: 5340944. DOI: 10.1155/2017/2197615. View